高级搜索
王雪, 袁芃, 岳健, 司怡然, 胡南林, 郑方超, 姜培娣. 20例晚期肿瘤患者免疫检查点抑制剂不良反应临床观察并文献复习[J]. 肿瘤防治研究, 2020, 47(6): 427-431. DOI: 10.3971/j.issn.1000-8578.2020.19.1554
引用本文: 王雪, 袁芃, 岳健, 司怡然, 胡南林, 郑方超, 姜培娣. 20例晚期肿瘤患者免疫检查点抑制剂不良反应临床观察并文献复习[J]. 肿瘤防治研究, 2020, 47(6): 427-431. DOI: 10.3971/j.issn.1000-8578.2020.19.1554
WANG Xue, YUAN Peng, YUE Jian, SI Yiran, HU Nanlin, ZHENG Fangchao, JIANG Peidi. Clinical Observation of Adverse Events of Immune Checkpoint Inhibitors in 20 Advanced Tumor Patients and Literature Reviews[J]. Cancer Research on Prevention and Treatment, 2020, 47(6): 427-431. DOI: 10.3971/j.issn.1000-8578.2020.19.1554
Citation: WANG Xue, YUAN Peng, YUE Jian, SI Yiran, HU Nanlin, ZHENG Fangchao, JIANG Peidi. Clinical Observation of Adverse Events of Immune Checkpoint Inhibitors in 20 Advanced Tumor Patients and Literature Reviews[J]. Cancer Research on Prevention and Treatment, 2020, 47(6): 427-431. DOI: 10.3971/j.issn.1000-8578.2020.19.1554

20例晚期肿瘤患者免疫检查点抑制剂不良反应临床观察并文献复习

Clinical Observation of Adverse Events of Immune Checkpoint Inhibitors in 20 Advanced Tumor Patients and Literature Reviews

  • 摘要:
    目的 观察免疫检查点抑制剂治疗的相关不良反应。
    方法 回顾性分析2017年3月—2019年8月在中国医学科学院肿瘤医院进行免疫检查点抑制剂治疗的20例晚期肿瘤患者临床资料,总结免疫检查点抑制剂治疗的相关不良反应。
    结果 20例患者免疫治疗中位时间为4.0月,发生较明确免疫治疗相关不良反应的共6例,中位时间5.3月,其中1例发生Ⅰ级免疫性胃肠炎,1例Ⅰ级免疫性皮炎,1例Ⅱ级免疫性甲状腺炎,1例Ⅲ级免疫性肝炎,1例Ⅲ级免疫性肺炎及1例Ⅳ级免疫性肺炎。
    结论 伴随免疫治疗的相关不良反应发生率较高,严重的不良反应甚至危及生命,故免疫相关不良反应的早发现、早诊断及早干预至关重要。

     

    Abstract:
    Objective To observe the toxicities of immune checkpoint inhibitors.
    Methods We retrospectively analyzed the clinical data of 20 advanced tumor patients who received immune checkpoint inhibitors therapy in Cancer Hospital of Chinese Academy of Medical Sciences from March 2017 to August 2019, and collected the immune-related adverse events.
    Results The median immunotherapy time was 4.0 months. The immune-related adverse events occurred in 6 patients: one case of grade Ⅰ gastroenteritis, one case of grade Ⅰ dermatitis, one case of grade Ⅰ thyroiditis, one case of grade Ⅲ hepatitis, one case of grade Ⅲ pneumonia and one case of grade Ⅳ pneumonia; the median time of occurrence was 5.3 months.
    Conclusion As the incidence of immune-related adverse events is relatively high and sometimes life-threatening, it is crucial for early recognition, accurate diagnosis and prompt intervention of the toxicities associated with immune checkpoint inhibitors.

     

/

返回文章
返回